Adoption of array technologies into the clinical laboratory.
Array-based methods are making substantial contributions to the discovery of disease biomarkers and are fueling the growth of multianalyte testing for disease diagnosis and treatment. The distillation of high-density array results into sets of signature markers promises to improve disease staging, risk stratification and treatment decisions. To accommodate the growing requirement for multiplex testing, clinical laboratories are converting several single-analyte tests into array-based formats. However, adoption of array technologies provides several challenges to the laboratory, which must evaluate these new formats, train laboratory personnel, market the new services and obtain reimbursement for new analytes. Liquid-bead arrays are an attractive format for routine clinical diagnostics due to a combination of appropriate analyte density, simultaneous array decoding and detection, and flexibility for rapid customization. In this review, the suitability of several array platforms to diagnostic testing and applications of liquid-bead arrays for cystic fibrosis testing, multidisease carrier status assays and leukemia subtyping are discussed. As our understanding of the clinical utility of new or established biomarkers and recommendations for testing change, flexibility and adaptability of array platforms will be imperative. Future development of novel assay formats and improved quantitation will expand the number of diseases tested and lead to further integration into the diagnostic laboratory.
Hadd
Andrew G
AG
Ambion Diagnostics, 2130 Woodward Street, Austin, TX 78744, USA. ahadd@ambion.com
Brown
Justin T
JT
Andruss
Bernard F
BF
Ye
Fei
F
WalkerPeach
Cindy R
CR
D005820:Genetic Testing; D006801:Humans; D007755:Laboratories, Hospital; D007938:Leukemia / Q000145:classification / Q000378:metabolism; D013677:Medical Laboratory Science / Q000379:methods*; D046228:Microarray Analysis / Q000379:methods*; D025202:Molecular Diagnostic Techniques / Q000379:methods*